Micro Interventional Devices, Inc. (MID) is developing a strategy for minimally invasive structural heart repair procedures
Micro Interventional Devices, Inc., (MID), based in Newtown, Pa., is an early-stage medical device company that designs, manufactures, and commercializes proprietary technologies targeting unmet needs in the treatment of structural heart diseases. MID is developing a disruptive technology that enables some heart surgeries to be conducted through a puncture in the skin as opposed to open surgery that sometimes involves opening the patient’s ribcage, creating possibilities for life-saving surgeries among patients who were not previously candidates. The new, minimally invasive structural heart repair procedure greatly reduces healing time. MID’s initial product is the PermasealTM device.
Permaseal is a novel transapical access and closure device that combines soft-tissue PolyCorTM anchors with advanced suture technology to provide automated ventricular access and closure during structural heart procedures such as Transcatheter Aortic Valve Replacement (TAVR). This reliable access and closure approach will reduce operating room time, abate blood loss, and simplify complex structural heart repair procedures, ultimately enabling a conversion from surgical procedures to less-invasive and simpler catheter lab-based procedures. It is estimated that the global transapical closure device market will exceed $400 million.